Genentech has reported positive results from the Phase III GiACTA clinical trial of Actemra (tocilizumab) to treat adults with giant cell arteritis (GCA).

Previously approved to treat active rheumatoid arthritis (RA) in adults, Actemra is an antagonist of the humanised interleukin-6 (IL-6) receptor.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GiACTA is a global, randomised, multi-centre, double-blind, placebo-controlled Phase III trial. It evaluated the efficacy and safety of subcutaneous Actemra in 251 subjects at 76 clinical centres in 14 countries.

Results showed that the trial met its primary and secondary endpoints with 53.1% of sustained remission at 52 weeks with biweekly Actemra and 56% when given weekly Actemra in combination with a 26-week steroid taper regimen.

“Actemra is an antagonist of the humanised interleukin-6 (IL-6) receptor.”

In case of patients who were administered a combination of placebo and a 26-week steroid taper regimen, sustained remission was found to be 14%.

The US Food and Drug Administration (FDA) approved subcutaneous Actemra for GCA treatment in May this year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Genentech chief medical officer and global product development head Sandra Horning said: “The data from GiACTA supported the FDA approval of the first new treatment option for patients with GCA in more than 50 years, and we are committed to continuing to explore new treatment options for autoimmune diseases with significant unmet medical need.”

During the GiACTA trial, the safety profile observed for Actemra was found to be consistent with its documented safety profile in other indications.

Actemra is studied as an intravenous administration in five Phase III trials with 4,000 RA patients in 41 countries and in two clinical trials as subcutaneous infusion for 1,800 RA subjects in 33 countries.

Image: Micrograph of giant cell arteritis. Photo: courtesy of Nephron.